Efficacy and safety of postoperative adjuvant chemotherapy with oxaliplatin for elderly patients: results from the CCOG-1302 study
Authors:
Open Access
- 17 March 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (6) , 1174-1182
Abstract
Background: Postoperative adjuvant chemotherapy using oxaliplatin in addition to 5-FU-based anticancer agents has become the standard treatment for colorectal cancer, however, there is insufficient evidence regarding the efficacy and safety of oxaliplatin combination therapy in the elderly patients. In this study, retrospective analysis of the results from the CCOG-1302 study was performed to confirm them. Methods: The patients in the CAPOX continuous (8 courses of CAPOX) and intermittent (2 courses of CAPOX + 4 courses of capecitabine + 2 courses of CAPOX) treatment arms in the CCOG-1302 study were divided into two groups, namely, the elderly (≥ 70) and non-elderly (< 70 years) groups. The adverse events, residual peripheral sensory neuropathy (PSN) and prognosis were analyzed. Results: The incidence of grade 3 or higher hematologic and non-hematologic toxicities in the continuous and intermittent treatment arm were not significantly different between the elderly and non-elderly groups. During the follow-up period, the percentages of grade I or higher PSN residuals were significantly higher among the elderly individuals in the continuous treatment arm at years 2, 3, 4, and 5. On the other hand, PSN decreased over time in the intermittent treatment arm as well as in the elderly and non-elderly patients. The 3-year DFS was not significantly different between the elderly and non-elderly groups in the continuous and intermittent treatment arms. Conclusion: Oxaliplatin combination chemotherapy can be safely administered to elderly patients. In addition, intermittent administration may be more useful in elderly individuals for the prevention of PSN.Keywords
Funding Information
- Nagoya University
This publication has 19 references indexed in Scilit:
- Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)European Journal of Cancer, 2021
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trialsThe Lancet Oncology, 2020
- Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trialSupportive Care in Cancer, 2017
- Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal CancerClinical Colorectal Cancer, 2017
- The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A Longitudinal StudyClinical Colorectal Cancer, 2017
- Peripheral neuropathy in the elderly2013
- Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA bindingNeuroToxicology, 2006
- Adjuvant Chemotherapy for Stage III Colon CancerJAMA, 2005
- Aging of phrenic nerve conduction in the elderlyClinical Neurophysiology, 2005
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001